FDA Issues Warning to Medline for Faulty Heart Syringes

• Medline received 221 complaints and filed 177 safety reports since June 2023, including one case of air injection into a patient and another involving clinician exposure to biohazards
• The FDA criticized Medline for rating the overall risk as low despite identifying air embolism (a potentially fatal condition) as the most serious possible failure in its own internal analysis
• Complaint rates rose throughout 2025 and breached Medline's safety limits every quarter before the company recalled the syringes in March 2026; the FDA warned of possible product seizures, court action, or financial penalties

Summary: FDA Warning to Medline Over Defective Heart Syringes

The U.S. Food and Drug Administration issued a warning letter to medical device manufacturer Medline on March 25, 2026, citing defective syringes used in cardiovascular procedures and inadequate corrective actions. The warning follows a December 2025 inspection at Medline's NAMIC division in Glens Falls, New York.

Key Issues:

The syringes, used to inject contrast dye during heart procedures, were found to disconnect from manifolds due to excess silicone on connectors. Complaints about this defect first surfaced in June 2023, but Medline failed to take appropriate remedial action.

Critical Data:

• 221 complaints received by Medline
• 177 safety reports filed with regulators
• Incidents included air injection into a patient and biohazard exposure to a clinician
• Complaint rates rose throughout 2025, breaching the company's safety limits every quarter
• Product recall eventually issued in March 2026

Regulatory Concerns:

The FDA highlighted that Medline's internal risk analysis identified air embolism—a potentially fatal condition—as the most serious possible failure, yet the company rated overall risk as "low," contradicting its own data. The agency also cited poor cleaning practices and inadequate safety testing following design changes.

Company Profile:

Medline, headquartered in Northfield, Illinois, has a market value of $56.7 billion. The company has not responded to requests for comment.

Market Implications:

The FDA warned that failure to address violations could result in product seizures, legal action, or financial penalties, posing potential regulatory and reputational risks for the major medical device manufacturer.